Clinical Investigator Development in Solid Tumor Oncology

描述（由申请人提供）：本提案的主要目的是为Spriggs博士及其在患者导向研究领域的职业发展活动提供工资支持。Spriggs博士目前领导着实体瘤小组，有12名初级教员（任命后三年内）。他每年还直接负责一名妇科研究员。斯普里格斯博士自己的研究计划的实验假设是，耐药性的元素是由基因表达的转录后调控控制的。这个实验室计划是由两个计划项目赠款的领导补充。在卵巢计划中，Spriggs博士领导了一个与卵巢癌复发后的再诱导相关的临床导向项目，作为他的RO1的扩展，该项目最初包含在卵巢PO1中。在癌症化疗项目中，他监督了4个项目的实施，这些项目分别针对1）HSP90靶向，2）组蛋白脱乙酰酶靶向，3）p53依赖性靶向和4）MAPK激酶通路的抑制。这两个项目，沿着MSKCC UO 1，形成了临床转化研究中研究员和初级教师发展的临床研究基础。这一建议是一个独特的机会，培训研究员在整合转录后耐药的实验室研究与靶向新药的初步临床研究。作为该计划的一部分，斯普里格斯博士是共同首席研究员与院长Bajorin博士的机构K30计划的临床研究和赠款写作的具体培训计划是为第一年的研究员和初级教师提供。在相关的活动中，我们提出了一种新的机制，用于评估医学肿瘤学教师，并建议收集一个固定的数据集，以创建基准，在MSKCC初级教师的进步。

DESCRIPTION (provided by applicant): The principal purpose of this proposal is to provide salary support for Dr. Spriggs and his career development activities in the area of patient oriented research. Dr Spriggs currently leads the solid tumor group with 12 junior faculty members (within three years of appointment). He also has direct responsibility for one Gyn Fellow annually. The experimental hypothesis of Dr. Spriggs' own research program is that elements of drug resistance are controlled by post transcriptional regulation of gene expression. This laboratory program is complemented by leadership of two program project grants. In the Ovarian Program, Dr. Spriggs leads a clinically oriented project related to re-induction following relapse in Ovarian cancer as an extension for his RO1 which was initially included in the Ovarian PO1. In the Cancer Chemotherapy Program, he supervises the conduct of 4 projects directed at 1) HSP90 targeting, 2) Histone deacetylase targeting, 3) p53 dependent targeting, and 4) Inhibition of the MAPK kinase pathways. These two programs, along with the MSKCC UO1, form the basis of clinical research for both fellows and junior faculty development in clinical translational research. This proposal represents a unique opportunity to train fellows in the integration of laboratory studies of post transcriptional drug resistance with the initial clinical studies of targeted new agents. As part of this program, Dr Spriggs is the co-principal investigator with Dr. Dean Bajorin of the institutional K30 program for clinical investigation and a specific training program in grant writing is provided for 1st year fellows and for junior faculty members. In a related activity, we propose a novel mechanism for the evaluation of medical oncology faculty and propose to collect a fixed data set to create benchmarks for advancement of junior faculty members at MSKCC.